SL Science Holding Limited
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving SL Science Holding Limited now
Current reporting with the operating signal separated from the noise.
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
The story matters when it changes SL Science Holding Limited’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.SL Science Holding Limited Reports Full Year 2025 Financial Results
The story matters when it changes SL Science Holding Limited’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest SLBT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
SL Science Holding Limited, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →